GI Innovation, Inc.

358570 · KOSDAQ

Public Market Listing

358570KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for GI Innovation, Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
CTLA-4 / IL-2RβγProtein / enzyme therapeutic
Non-Small Cell Lung Cancer
Phase 1/2
CTLA-4 / IL-2RβγProtein / enzyme therapeutic
Non-Small Cell Lung CancerCervical CancerRenal Cell CarcinomaBladder / Urothelial Cancer
Clear Cell Renal Cell Carcinoma, Urothelial Carcinoma
Phase 1/2
CD73 / IL-2RβγMultispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
GI-108Phase 1/2Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic Cancer …
Est. primary completion 2027-02 · NCT07172802 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Efdelikofusp alfa + GI-101APhase 1/2Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC) …
Est. primary completion 2028-06-30 · NCT04977453 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.